ClinicalTrials.gg
RecruitingNCT07505173HOPE-WBRTUpdated Apr 1, 2026

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

A Phase 2 interventional study of Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O and Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer in Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital — 24 open to participants now, 25 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Tianjin Medical University Cancer Institute and Hospital.

Planned enrollment
13th of 48
74 · median 52
Started
2026
with 6 others
Phase 2
33 of 50
19 open now
Primary completion
2028-01
later than 20 of 24 live
Registered
46th of 50
by date

Among the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, this one is the 13th largest by planned enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 20 of the 24 other live ones, and was the 46th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

24 of the 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital are open now, in 1 country. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Carcinoma, Non-Small-Cell Lung by Tianjin Medical University Cancer Institute and Hospital, or all of them as a file.
02

Study summary

This is a single-arm, multicenter, open-label, phase Ⅱ exploratory clinical study, which plans to enroll 74 treatment-naive patients with EGFR-sensitive mutations (exon 19 deletion, exon 21 L858R mutation) and symptomatic brain metastases from non-small cell lung cancer (NSCLC). The primary objective is to evaluate the intracranial progression-free survival (iPFS) of hippocampal-sparing whole-brain radiotherapy (PTV: 20Gy/10 fractions) combined with simultaneous integrated boost to brain metastases (PGTV: 40Gy/10 fractions) plus osimertinib (80mg orally once daily). The secondary objectives are to assess efficacy indicators including overall progression-free survival (PFS), intracranial/systemic objective response rate (ORR), as well as safety. The primary endpoint is iPFS, supplemented by secondary endpoints such as PFS, ORR, disease control rate (DCR), overall survival (OS), adverse events (AE) evaluated per NCI-CTCAE v5.0 criteria, and neurocognitive function scores (MMSE/HVLT-R). By optimizing the combined mode of radiotherapy and targeted therapy, this study aims to provide a safer and more effective treatment option for such patients, balancing tumor control and quality of life protection.

Read the detailed description
  1. Study Rationale Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, with the central nervous system being one of the most common metastatic sites. Among NSCLC patients, those with epidermal growth factor receptor (EGFR)-sensitive mutations (exon 19 deletion and exon 21 L858R mutation) face a significantly higher risk of brain metastasis, with a 3-year cumulative incidence ranging from 29.4% to 60.3%. With the widespread application of third-generation tyrosine kinase inhibitors (TKIs), the median progression-free survival (PFS) of advanced EGFR-mutated NSCLC patients has been extended to over 24 months, but brain metastasis has become the most prominent failure mode due to the limited blood-brain barrier penetration of conventional treatments.

    Current radiotherapy strategies for brain metastasis have inherent limitations: stereotactic radiosurgery (SRS) for ≤4 lesions is associated with a >50% risk of distant intracranial recurrence and increased radiation necrosis when combined with TKIs, while conventional whole-brain radiotherapy (WBRT) for >4 lesions results in suboptimal local tumor control and irreversible neurocognitive impairment, primarily attributed to hippocampal damage. Osimertinib, a third-generation EGFR-TKI, exhibits superior cerebrospinal fluid penetration (2.5%-16%) compared to first and second-generation agents, demonstrating potent intracranial efficacy. Hippocampal-sparing whole-brain radiotherapy with simultaneous integrated boost (HS-WBRT+SIB) is a novel technique that restricts the hippocampal mean dose to ≤9Gy (maximum dose ≤16Gy) while delivering a boosted dose to metastatic lesions, which has been shown to reduce cognitive decline risk (hippocampal metastasis rate only 1.4%-4.5%) and improve local control.

    Preclinical and clinical evidence indicates that radiotherapy can disrupt the blood-brain barrier to enhance intracranial drug concentration, while TKIs can sensitize tumors to radiation, forming a synergistic therapeutic effect. However, there remains an unmet clinical need for an optimized combined strategy for symptomatic brain metastases in treatment-naive EGFR-mutated NSCLC patients. This study aims to validate the efficacy and safety of HS-WBRT+SIB combined with osimertinib, addressing the limitations of current treatments and providing a more effective and tolerable therapeutic option.

  2. Study Design 2.1 Trial Type Prospective, single-arm, multicenter, open-label, phase Ⅱ exploratory clinical trial (Investigator-Initiated Trial, IIT; Non-IND).

    2.2 Study Period Expected start date: October 2025 Expected end date: October 2027 Total duration: 2 years, including a 24-month survival follow-up period after treatment completion or progression.

    2.3 Study Sites Tianjin Medical University Cancer Institute and Hospital (leading site), Tianjin Chest Hospital, and Tianjin Huanhu Hospital.

    2.4 Study Population 2.4.1 Target Population Treatment-naive patients with EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation) and symptomatic brain metastases from NSCLC.

    2.4.2 Sample Size A total of 74 patients are planned to be enrolled. The sample size is calculated based on the primary endpoint of intracranial progression-free survival (iPFS), with a historical control iPFS of 17 months (derived from the FLAURA2 study's cEFR cohort). Assuming a two-sided α of 0.1, power of 0.8, 24-month enrollment and follow-up periods, and a 10% dropout rate, the required sample size is 74 patients (66 evaluable cases plus 8 dropouts).

  3. Intervention Measures 3.1 Radiotherapy Regimen Technique: Hippocampal-sparing whole-brain radiotherapy with simultaneous integrated boost (HS-WBRT+SIB).

    Dose: Planning Target Volume (PTV, whole brain): 20 Gy in 10 fractions; Planning Gross Target Volume (PGTV, brain metastases): 40 Gy in 10 fractions.

    Fractionation: Once daily, 5 days per week, consecutive radiotherapy. Hippocampal Dose Constraints: Mean dose (Dmean) ≤9 Gy (acceptable ≤10 Gy); Maximum dose (Dmax) ≤16 Gy (acceptable ≤17 Gy).

    3.2 Drug Regimen Study Drug: Osimertinib mesylate tablets (Tagrisso®). Dosage and Administration: 80 mg orally once daily, taken within 30 minutes after breakfast, 28 days as one cycle.

    Timing of Radiotherapy: Initiated within 28 days after the first dose of osimertinib.

    Duration: Continuous administration until disease progression, intolerable toxicity, withdrawal of informed consent, or investigator-determined termination.

    Dose Adjustment: For grade ≥3 adverse events (AEs) per NCI-CTCAE v5.0, treatment may be interrupted or dose reduced to 40 mg/day. Missed doses are not made up; subsequent doses are administered as scheduled.

    3.3 Concomitant Medications Avoid concurrent use of strong CYP3A4 inducers (e.g., rifampicin, phenytoin) and St. John's Wort. If unavoidable, osimertinib dose may be increased to 160 mg/day and restored to 80 mg/day 3 weeks after discontinuing the inducer.

    Caution with P-gp/BCRP substrates (e.g., digoxin, dabigatran) and QT-prolonging drugs (e.g., fluoroquinolones, amiodarone); close monitoring is required.

    Acid-suppressing agents may be used without dose adjustment.

  4. Outcome Measures 4.1 Primary Endpoint Intracranial Progression-Free Survival (iPFS): Time from treatment initiation to first documented intracranial disease progression, worsening of previously controlled intracranial hypertension, or death from any cause.

    4.2 Secondary Endpoints 4.2.1 Efficacy Indicators Overall Progression-Free Survival (PFS): Time from treatment initiation to first documented systemic disease progression or death from any cause.

    Intracranial/Systemic Objective Response Rate (ORR): Proportion of patients achieving complete response (CR) or partial response (PR) per RECIST v1.1.

    Intracranial/Systemic Duration of Response (DoR): Time from first confirmation of CR/PR to disease progression or death.

    Intracranial/Systemic Disease Control Rate (DCR): Proportion of patients achieving CR, PR, or stable disease (SD) per RECIST v1.1.

    Overall Survival (OS): Time from treatment initiation to death from any cause. 4.2.2 Safety Indicators Adverse Events (AEs)/Serious Adverse Events (SAEs): Assessed and graded per NCI-CTCAE v5.0, including onset time, severity, duration, management, and outcome.

    Neurocognitive Function: Evaluated by Mini-Mental State Examination (MMSE) and Hopkins Verbal Learning Test-Revised (HVLT-R).

    Performance Status: ECOG score assessed at each cycle. Quality of Life (QoL): Evaluated by EORTC QLQ-C30 questionnaire. Laboratory Tests: Routine blood, biochemistry, coagulation, and cardiac function (echocardiogram) at specified time points.

  5. Study Procedures 5.1 Screening Period (Day -14 to Day 1) Obtain informed consent, review medical history, and perform physical examination.

    Conduct baseline assessments: ECOG score, MMSE, HVLT-R, EORTC QLQ-C30, vital signs, EGFR gene testing, contrast-enhanced brain CT/MRI, chest CT/PET-CT, abdominal/neck ultrasound, laboratory tests (hematology, biochemistry, coagulation), and echocardiogram.

    5.2 Treatment Period (28-day cycles) Initiate osimertinib administration on Day 1; start radiotherapy within 28 days.

    Cycle Assessments: Routine blood (weekly for the first 2 cycles, then per cycle), biochemistry (Cycle 1 Day 15 and end of each cycle), ECOG score, MMSE, HVLT-R, and AE monitoring at each visit.

    Efficacy Evaluation: Contrast-enhanced brain CT/MRI and chest CT every 3 cycles (±7 days) per RECIST v1.1.

    5.3 Follow-up Period Safety Follow-up: Continue monitoring AEs, laboratory tests, and QoL until 30 days after treatment discontinuation.

    Survival Follow-up: Telephone follow-up every 3 months for 24 months to collect survival status and subsequent antitumor treatments.

  6. Statistical Analysis 6.1 Analysis Populations Full Analysis Set (FAS): All enrolled patients who received at least one dose of osimertinib.

    Per-Protocol Set (PPS): Subset of FAS without major protocol violations. Safety Set (SS): All enrolled patients who received at least one dose of osimertinib and had at least one post-baseline safety assessment.

    6.2 Statistical Methods Descriptive Statistics: Continuous data (e.g., age, laboratory values) summarized as mean, standard deviation, median, min/max; categorical data (e.g., AE incidence) as frequency and percentage.

    Time-to-Event Analysis: iPFS, PFS, and OS estimated by Kaplan-Meier method with 95% confidence intervals (CIs).

    Efficacy Indicators: ORR and DCR presented as point estimates with 95% CIs. Safety Analysis: AE incidence summarized by frequency and percentage; changes in laboratory parameters and neurocognitive scores described descriptively.

  7. Quality Assurance and Data Management Compliance with Good Clinical Practice (GCP), Declaration of Helsinki, and local regulations. Protocol revisions require ethical committee approval.

    Regular monitoring by clinical research associates to ensure data accuracy, completeness, and protocol adherence.

    Electronic Data Capture (EDC) system used for data collection; database locked after verification by investigators, data managers, and statisticians.

    Study records (informed consent forms, CRFs, laboratory reports) retained per regulatory requirements.

  8. Study Termination and Withdrawal 8.1 Patient Withdrawal Voluntary withdrawal by the patient. Intolerable toxicity or adverse events. Disease progression (radiological or clinical). Pregnancy or loss to follow-up. Investigator-determined withdrawal (e.g., protocol violation, new comorbidities).

8.2 Study Termination Unacceptable or unexpected risks to patients. Major protocol design flaws identified during implementation. Lack of therapeutic efficacy deemed futile by the investigator. Early termination by the ethical committee or regulatory authorities.

03

Conditions studied

  • Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases

Keywords

  • EGFR exon 21 L858R mutation
  • Non-small cell lung cancer (NSCLC)
  • EGFR-sensitive mutation
  • EGFR exon 19 deletion
  • Symptomatic brain metastasis
  • Hippocampal-sparing whole-brain
  • radiotherapy (HS-WBRT)
  • Simultaneous integrated boost (SIB)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed a written form prior to enrollment;
  • Aged 18-75 years;
  • Histopathologically confirmed non-small cell lung adenocarcinoma (NSCLC); EGFR gene test confirmed EGFR sensitive mutations, including exon 19 deletion (19del) and exon 21 L858R mutation (verified and confirmed by investigators at the respective study centers);
  • confirmed by contrast-enhanced cranial CT/MRI; the number of brain lesions requiring local dose escalation is 1-10, with at least one measurable intracranial lesion having a diameter ≥10 mm; the distance between metastatic lesions and important cerebral functional areas meets radiotherapy-related requirements; at least one (per v1.1 criteria) confirmed by contrast-enhanced extracranial CT/PET-CT;
  • Symptomatic brain metastasis;
  • performance status score: 0-2;
  • Expected survival time of no less than 12 weeks;
  • No prior anti-tumor treatment received for NSCLC;
  • Normal function of vital organs, meeting the following requirements (no blood components or cell growth factors administered within 14 days):

A) Routine blood test criteria: ≥100 g/L; ≥1.5×10⁹/L; ≥75×10⁹/L; B) Biochemical test criteria: ≤1.5× (upper limit of normal); and AST ≤2.5×ULN (for patients with liver metastasis, ALT and AST ≤5×ULN); serum creatinine ≤1.5×ULN, rate ≥50 ml/min (calculated based on the Cockroft-Gault formula); C) Coagulation function criteria: ≤1.5×ULN and APTT ≤1.5×ULN; D) Cardiac color Doppler ultrasound: (LVEF) ≥50%;

- For non-surgically sterilized patients or women of : a medically approved method (e.g., intrauterine device, oral contraceptives, or condoms) must be used during the study treatment period and for 3 months after the end of study treatment; non-surgically sterilized women of childbearing potential must have a negative serum or urine HCG test within 7 days prior to study enrollment, and must not be breastfeeding.

All subjects voluntarily participate in the study, with good compliance and willingness to cooperate with safety and overall survival follow-up.

Exclusion criteria

Exclusion Criteria:

  • Presence of uncontrollable third space effusion (e.g., pleural effusion, ascites) that cannot be managed with drainage or other interventions;
  • Presence of multiple factors impairing oral drug administration and absorption (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea, intestinal obstruction, etc.);
  • Patients who are known to be pregnant, planning pregnancy, or women of who refuse to adopt effective measures throughout the study period;
  • Patients with severe concomitant diseases or those deemed ineligible for enrollment by the investigator;
  • Patients with meningeal ;
  • Participation in other drug clinical trials within 4 weeks prior to enrollment;
  • Concurrent receipt of other anti-tumor therapies;
  • A known history of psychotropic drug abuse, alcoholism, or drug addiction in the subject;
  • Underlying diseases that may interfere with study drugs (e.g., electrocardiographic abnormalities, active interstitial lung disease);
  • Any other conditions deemed by the investigator to potentially harm the subject or render them unable to meet or comply with the study requirements.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O

    Other: Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O · Drug: Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer

Interventions

  • OtherHippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O

    Hippocampal-Sparing Whole-Brain Radiotherapy + Simultaneous Integrated Boost to Brain Metastases + O

  • DrugHippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer

    Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer

This study also gives OsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Intracranial progression-free survival (iPFS )

    iPFS is defined as the time from the date of randomization to the date of the first objectively documented intracranial tumor progression or death due to any cause.

    Time frame: 36 months

Secondary outcomes

  1. Overall survival (OS)

    OS is the length of time from the date of randomization until death from any cause.

    Time frame: 36 months

Other outcomes

  1. Systemic PFS

    Systemic PFS is defined as the time from the date of randomization to the date of the first objectively documented systemic tumor progression or death due to any cause.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 24 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Apr 1, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505173
Collaborators
Tianjin Chest Hospital, Tianjin Huanhu Hospital
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Jan 1, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Apr 1, 2026

Study contacts

pang qingsong Chief Physician, PhD
Contact
pangqingsong@tjmuch.com
18622221203

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion